Difference between revisions of "Main Page Mobile"
Warner-admin (talk | contribs) m (Text replacement - "[[Castleman’s" to "[[Castleman") |
Warner-admin (talk | contribs) m (Text replacement - "http://hemonc.org" to "https://hemonc.org") |
||
(7 intermediate revisions by the same user not shown) | |||
Line 3: | Line 3: | ||
='''HemOnc.org - A Free Hematology/Oncology Reference'''= | ='''HemOnc.org - A Free Hematology/Oncology Reference'''= | ||
− | '''<big><big>This is an obsolete page which is no longer needed since the software that runs this site now offers better built-in support for mobile/phone/tablet users. For posterity, this page will remain here for now. <br>[ | + | '''<big><big>This is an obsolete page which is no longer needed since the software that runs this site now offers better built-in support for mobile/phone/tablet users. For posterity, this page will remain here for now. <br>[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile If you wish to use the mobile version of the site, click here]. |
</big></big>''' | </big></big>''' | ||
<center> | <center> | ||
Line 41: | Line 41: | ||
|- | |- | ||
|style="height:50px" |[[Melanoma]] | |style="height:50px" |[[Melanoma]] | ||
− | |[[ | + | |[[Malignant pleural mesothelioma]] |
|- | |- | ||
|style="height:50px" |[[Neuroendocrine tumor]] | |style="height:50px" |[[Neuroendocrine tumor]] | ||
Line 74: | Line 74: | ||
|colspan="2" align="center" style="background-color:#FF0D00"| '''Myeloproliferative neoplasms and myelodysplastic syndromes''' | |colspan="2" align="center" style="background-color:#FF0D00"| '''Myeloproliferative neoplasms and myelodysplastic syndromes''' | ||
|- | |- | ||
− | |style="height:50px" |[[Chronic | + | |style="height:50px" |[[Chronic myeloid leukemia | Chronic myelogenous leukemia (CML)]] |
|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]] | |[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]] | ||
|- | |- | ||
Line 97: | Line 97: | ||
|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]] | |[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]] | ||
|- | |- | ||
− | |style="height:50px" |[[Extranodal NK | + | |style="height:50px" |[[Extranodal NK- and T-cell lymphoma, nasal type]] |
|[[Follicular lymphoma|Follicular lymphoma (FL)]] | |[[Follicular lymphoma|Follicular lymphoma (FL)]] | ||
|- | |- | ||
Line 103: | Line 103: | ||
|[[HIV-associated lymphoma]] | |[[HIV-associated lymphoma]] | ||
|- | |- | ||
− | |style="height:50px" |[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]] | + | |style="height:50px" |[[Classical Hodgkin lymphoma|Hodgkin lymphoma (HL)]] |
|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]] | |[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]] | ||
|- | |- | ||
Line 115: | Line 115: | ||
|[[Multiple myeloma|Multiple myeloma (MM)]] | |[[Multiple myeloma|Multiple myeloma (MM)]] | ||
|- | |- | ||
− | |style="height:50px" |[[NK | + | |style="height:50px" |[[NK- and T-cell lymphoma]] |
|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]] | |[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]] | ||
|- | |- | ||
Line 135: | Line 135: | ||
|[[Histiocytoses]] | |[[Histiocytoses]] | ||
|- | |- | ||
− | |style="height:50px" |[[ | + | |style="height:50px" |[[Paroxysmal_nocturnal_hemoglobinuria]] |
− | |[[ | + | |[[Venous_thromboembolism]] |
|- | |- | ||
|} | |} |
Latest revision as of 19:32, 23 June 2024
HemOnc.org - A Free Hematology/Oncology Reference
This is an obsolete page which is no longer needed since the software that runs this site now offers better built-in support for mobile/phone/tablet users. For posterity, this page will remain here for now.
If you wish to use the mobile version of the site, click here.
4,428 regimens on HemOnc.org |
6,544 variants on HemOnc.org
|
How to add a HemOnc.org shortcut to your mobile device's home screen
Created by oncologists as a knowledge base for providers, this site contains reference notes prepared by their peers and allows people to share wisdom and insights from their own clinical experiences for the benefit of all. This shared online notebook will continue to evolve and grow to meet the needs of the community because users such as yourself are able to refine and build upon existing content. Please see the desktop version of the main page for more information about HemOnc.org.